Abstract: Objective：To further understand the diagnosis, clinical features and prognosis of myeloid neoplasms with erythroblast more than 50% of bone marrow(BM) nucleated cells in the WHO Classification(2016) by analyzing the clinical data, diagnosis and prognosis of 3 patients with myeloid leukemia. Methods：The ages, medical histories, symptoms and signs, and laboratory examinations from 3 patients with myeloid neoplasms whose erythroblast cells were more than 50% of BM nucleated cells when newly diagnosed were collected. Then, they were diagnosed with the WHO Classification criteria(2008) and the WHO Classification criteria(2016), respectively, and their prognosis was evaluated with the revised International Prognostic Scoring System(IPSSR). Results：According to the WHO Classification criteria(2008), all of 3 patients were diagnosed as acute erythroid leukemia(AEL). However, according to the WHO Classification criteria(2016), 2 patients were diagnosed as myelodysplastic syndrome with excess blasts-2(MDS-EB-2), and 1 was diagnosed as acute myeloid leukemia(AML) with maturation. Moreover, their prognostic scores were also different. The former two patients were older men with significant dysplasia and complex genetic abnormalities, and had poor prognosis, while the latter was a middleaged woman with no obvious dysplasia and genetic abnormalities, and had medium prognosis. Conclusion：The WHO Classification(2016) is more reasonable than the WHO Classification(2008), which tends to focus more on the different biological characteristics of diseases, and may better distinguish two types of diseases with different clinical features and prognosis.